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Abstract
Dyslipidemia is a potential complication of long-term usage of antiretroviral therapy (ART)
and also known to be associated with genetic factors. The host genetic variants associated
with dyslipidemia in HIV patients on ART in Ghana have not been fully explored. The study
constituted a total of 289 HIV-infected patients on stable ART for at least a year. Fasting
blood was collected into EDTA tube for lipids measurement. Lipid profiles were used
to define dyslipidemia based on the NCEP-ATP III criteria. HIV-infected subjects were
categorized into two groups; those with dyslipidemia (cases) (n = 90; 31.1%) and without
dyslipidemia (controls)(n = 199; 68.9%). Four candidate single nucleotide polymorphism
(SNP) genes (ABCA1-rs2066714, LDLR-rs6511720, APOA5-rs662799 and DSCAML1rs10892151) were determined. Genotyping was performed on isolated genomic DNA of
study participants using PCR followed by a multiplex ligation detection reaction (LDR). The
percentage of the population who had the rare homozygote alleles for rs6511720 (T/T),
rs2066714 (G/G), rs10892151 (T/T) and rs662799 (G/G) among case subjects were 5.5%,
14.4%, 6.6% and 10.0% whiles 2.0% 9.1%, 6.5% and 4.0% were observed among control
subjects. There were statistically significant differences in the genotypic prevalence of
APOA5 (p = 0.0357) and LDLR polymorphisms (p = 0.0387) between case and control
subjects. Compared to the AA genotype of the APOA5 polymorphisms, individuals with the
rare homozygote genotype [aOR = 2.38, 95%CI(1.06–6.54), p = 0.004] were significantly
associated with an increased likelihood of developing dyslipidemia after controlling for
age, gender, treatment duration, CD4 counts and BMI. Moreover, individuals with the rare
homozygous genotype of ABCA1 (G/G) [aOR = 10.7(1.3–88.7), p = 0.0280] and LDLR
(rs6511720) G>T [aOR = 61.2(7.6–493.4), p<0.0001) were more likely to have high levels of
total cholesterol levels. Our data accentuate the presence of SNPs in four candidate genes
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and their association with dyslipidemia among HIV patients exposed to ART in the Ghanaian
population, especially variants in APOA5-rs662799 and LDLR rs6511720 respectively.
These findings provide baseline information that necessitates a pre-symptomatic strategy
for monitoring dyslipidemia in ART-treated HIV patients. There is a need for longitudinal
studies to validate a comprehensive number of SNPs and their associations with
dyslipidemia.

Introduction
Global estimates report 37 million people living with Human Immunodeficiency Virus (HIV),
out of which about 26 million reside in Sub-Saharan (SSA) [1]. In Ghana, HIV prevalence
among adults aged 15–49 years has declined from about 2.4% in 2013 to 1.6% in 2015 according to the World Bank report [2]. The life expectancy of HIV-infected patients has increased
remarkably due to the use of antiretroviral therapy (ART) as a standard of care [3–5]. Unfortunately, long term ART use is associated with a wide spectrum of metabolic disturbances such
as lipodystrophy, insulin resistance, and dyslipidemia [6–8]. Dyslipidemia is defined by elevations in total cholesterol, low-density lipoprotein cholesterol (LDL-C), triglycerides and
decreased high-density lipoprotein cholesterol (HDL-C).
The prevalence of dyslipidemia is reportedly higher in people living with HIV due to the
effect of ART in Ghana [9–11]. The severity of dyslipidemia and the typical pattern of the lipid
profile differ between and within the classes of antiretroviral (ARV) agents [12]. Lipid abnormalities have been reported to be frequently associated with HIV-infected individuals receiving protease inhibitors (PIs) and treatment-naïve HIV-infected patients, suggesting that HIV
infection itself has a metabolic deleterious effect. Such reported side effects are not universal to
all individuals on ART and may even vary in individuals with comparable ART, demographic,
immunologic and virological characteristics [12–14]. This variability suggests that genetic factors and inherited predispositions may have a significant influence on the incidence of metabolic dysfunction [14, 15]. However, high HDL cholesterol and apolipoprotein A-I (APOA-I)
have been directly associated with a better immunological outcome [16].
Low-density lipoprotein receptor (LDLR), positioned on chromosome 19p13.2 plays a significant role in lipoprotein metabolism by mediating the uptake of cholesterol through the
binding and subsequent cellular uptake of apolipoprotein-E and B- constituting lipoproteins.
Mutations have been detected in different domains of the LDLR which have a distinct effect
on LDLR structure and function [17, 18]. ATP-binding cassette A1(ABCA1) plays a critical
role in the reverse cholesterol transport system. Mutation in ABCA1, that encodes this protein,
along with genes responsible for their transcription regulation, can lead to abnormality in the
metabolism of lipids [19, 20]. Apolipoprotein A5 (APOA5) has been shown to be a key regulator of plasma triglycerides and there are several SNPs associated with the APOA5 gene [21,
22]. Moreover, HIV-infected patients who harbor polymorphisms of the DSCAML1 (Down
syndrome cell adhesion molecule like-1) gene exhibit a less favorable lipids profile [23, 24].
Current studies have suggested the relationship between the level of lipids and LDLR, ABCA1
APOA5, and DSCAML1 polymorphisms [15, 25].
Nevertheless, the exact mechanism of dyslipidemia is not fully understood but is most likely
multifactorial with the genetic variation being shown to account for about 43–83% of the variability of plasma lipoprotein levels in a normal healthy population [16, 26]. Therefore, from
the genetic perspective, HAART-associated hyperlipidemia could be under the influence of
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various forms of genetic polymorphisms, similar to that in non-HIV adults [27, 28]. Several
single nucleotide polymorphisms (SNPs) that could account for a significant portion of the
variation of blood lipoprotein concentrations have been identified through recent candidate
gene studies and genome-wide association studies (GWAS)[15, 29].
The association between gene polymorphisms that may signal a predisposition to lipid
abnormalities and clinical progression of HIV infection has not been thoroughly studied in
Africa where the prevalence of HIV is on the increase. SNP prevalence differs by population
and at present, the majority of the SNP-associated dyslipidemic studies among HIV patients
have come from non-African countries with only a few of these studies emanating from Africa
[15, 24, 30]. To the best of our knowledge, no published study has explored the genetic variants
and markers associated with dyslipidemia in HIV-infected individuals on HAART in a Ghanaian population. This study, therefore, investigated the distribution of SNPs in four candidate
genes that have had significant published lipid associations and their resultant associations
with plasma lipid levels in Ghanaian HIV-infected patients on HAART. An understanding of
the impact of host genetic factors on the prevalence of dyslipidemia in a cohort of HIVinfected individuals on HAART would promote interventions in the scaling up of treatment
regimen.

Material and methods
Study design and subjects
This study comprised HIV-1 infected patients who were on ART regimen for at least one year,
with either a protease inhibitor (PI) or non-nucleoside reverse-transcriptase inhibitor
(NNRTI) backbone without any history of dyslipidemia, hypertension, and diabetes. The
NCEP-ATP III criteria were used to defined dyslipidemia among the HIV seropositive [31].
The HIV seropositive subjects were categorized into two groups; those with dyslipidemia
(cases) and without dyslipidemia (controls). The adjuvant antiretroviral drugs were stavudine,
lamivudine, and zidovudine with priorities for inclusion being given to participants who consented to undergo biochemical and genetic testing. Pregnant women, patients being treated
with lipid-lowering drugs and those with neurological conditions that prevented them from
understanding the concept of the research were excluded from the study.

Sample size determination
Based on previous report from a study conducted on the burden of dyslipidemia among adults
in Ghanaian a population [32] and the lack of knowledge of the frequency of polymorphisms
in the population, we assumed an expected proportion of 0.1 for exposure in HIV seropositive
subjects with dyslipidemia, an assumed odds ratio of 2, a confidence interval of 95%, a power
of identifying a significant difference between two groups, and 1:3 ratio, a total of 289 subjects
were recruited.

Data collection and biochemical analysis
A structured questionnaire was administered to each patient to obtain demographic information. Details on ARVs, time of diagnosis, duration on ARVs, CD4 counts were obtained from
the medical folders of the patients. Fasting blood samples were collected for the analysis of
lipid parameters and genomic DNA.
Blood samples were taken after an overnight (12–14 hours) fast into EDTA tubes for biochemical analysis. Fasting lipid panel including total cholesterol (TC), HDL-cholesterol and
triglycerides (TG) were measured using Flexor junior (Vital Scientific, Dieren, Netherlands)

PLOS ONE | https://doi.org/10.1371/journal.pone.0227779 January 13, 2020

3 / 15

Association of single nucleotide polymorphisms with dyslipidemia in antiretroviral exposed HIV patients

chemistry autoanalyzer. LDL-C was calculated from the Friedewald’s formula, LDL-C = TC(HDL-C- TG/2.2). Patient with triglycerides above 4.52 mmol/L was not included in the study
since LDL-C was not directly measured and due to the deficit of the Friedewald’s equation,
which overestimates LDL-C levels when triglycerides are high. This is to reduce any bias that
might affect the relationship found between LDL-C and dyslipidemia. The NCEP-ATP III criteria were used to define dyslipidemia as reduced HDL (<1.03 mmol/L in males; <1.29 mmol/
L in females), raised TG �1.7 mmol/L, TC >6.2 mmol/L and LDL-C >3.37 mmol/L or specific
treatment for such lipid abnormalities [31].

Anthropometric and hemodynamic measures
Anthropometric measures such as weight and height were performed using an automated
weighing scale. Portable height rod stadiometers were used for height measurements to the
nearest centimeter. Body mass index (BMI) was defined as weight (kg)/height (m)2. Blood
pressure was measured using an automated sphygmomanometer (Omron M7 Intelli IT).
Three consecutive readings of blood pressure measurements were taken from the patients’
right arm and the mean of two closest values was recorded.

Single nucleotide polymorphisms selection and genotyping
The four candidate SNPs (rs2066714, rs6511720, rs662799, and rs10892151) selected for this
study have been shown in previous studies to be significantly associated with lipid serum
abnormalities following a review of GWAS and PubMed reports of SNPs associated with dyslipidemia among HIV-infected individuals [24, 33–35]. Genomic DNA was isolated from
EDTA-collected whole blood samples of study participants using the Qiagen midi kit prep as
per manufacturer’s protocol. Genotyping was carried out on isolated genomic DNA of study
participants using a multiplex ligation detection reaction (LDR), a sequence-specific genotyping method that has been used efficiently in polymorphism typing and detection of mutations
in disease genes [36]. Triplex multiplex reaction assays were setup with products being run on
10% polyacrylamide gel for LDR genotype observation (58 to 90 base pairs). The LDR products
differed in sizes of about 8 base pairs for each triplex (Fig 1). The runs were controlled with
Amelogenin XY (AME XY) to determine a successful reaction and gender-confirming for
study participants.
Allele specific LDR products are assigned by color and size following 10% polyacrylamide
gel electrophoresis. Each band as shown in the image represents a specific genotype of each
allele. At the bottom of the gel are leftover LDR probes from the reaction mix as represented
by shared common bands (Fig 1).

Fig 1. A representative gel depicting a genotype assay using triplex ligation detection reaction.
https://doi.org/10.1371/journal.pone.0227779.g001
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Ethical consideration
The study protocol was approved by the Committee of Human Publication and Research Ethics of the School of Medical Sciences, Kwame Nkrumah University of Science and Technology,
Kumasi, Ghana. All participants gave written informed consent and were assured that the
information gathered was to be used strictly for research and academic purpose only. In addition, respondents were given the freedom to opt-out at any time they thought they could not
continue with the study.

Data management and statistical analysis
The NCEP-ATP III criteria were used to defined dyslipidemia among the HIV seropositive
[32]. The HIV seropositive subjects were categorized into two groups; those with dyslipidemia
(cases) and without dyslipidemia (control). Microsoft Excel software was used to set up a database, and to avoid entry error, the double-entry method was used, and data were analyzed
using SPSS version 25 and R program where appropriately. Parametric continuous were analyzed with a t-test and expressed as mean ± standard deviation (SD) after checking for normality with the Kolmogorov-Smirnov test.
ANOVA was used to compare continuous variables from more than two groups with Yates
post-test, the chi-square test was to compare differences between more than three groups for
categorical variables while Fisher exact was used to assess differences between two groups for
categorical variables Allele frequencies were estimated by gene counting. Deviations in the
genotype frequencies from the Hardy-Weinberg equilibrium (HWE) were tested using the
chi-square (χ2) analysis. Initial univariate binary logistic models were performed to determine
the association between SNPs and dyslipidemia, followed by adjusted multivariate binary
logistic models controlling for age, gender, BMI, CD4 counts and duration of HIV infection.
Adjusted multivariate binary logistic models were used also to identify SNPs independently
associated with lipid abnormalities holding confounding variables constant. A p-value of less
than 0.05 was considered statistically significant.

Results
Table 1 shows a comparison of demographic, hemodynamic indices, lipid parameters, dyslipidemic indices between cases and control subjects. Dyslipidemia was found in 31.1% (90/289).
A statistically significant difference between case and control subjects was observed with
regards to age (p = 0.0328). There were more females than males in the study population
(p>0.05). The average duration of treatment among the subjects was 4 years. There were statistically significant differences between the case and control subjects in relation to CD4 counts
(p = 0.0010) and BMI (p<0.0001). The case subjects had significantly higher levels of TC
(p<0.000) LDL-C (p<0.0001) and CR (p<0.0001) compared to the control subjects. Compared to HIV seropositive subjects with dyslipidemia, those without dyslipidemia had significantly increased levels of HDL-C (0.7 ±0.3 vs. 1.2±0.5, p<0.0001).
Table 2 shows the frequency distribution of the genotypes and alleles of the four SNPs. The
percentage of the population who had the rare homozygote alleles for rs6511720 (T/T),
rs2066714 (G/G), and rs10892151 (T/T) and rs662799 (G/G) among the case subjects were
5 .5%, 14.4%, 6.6% and 10.0% whiles 2.0% 9.1%, 6.5% and 4.0% were observed among the
control subjects. Statistically significant differences in allelic frequency were observed for
DSCAML1 (p = 0.0008)and APOA5 (p = 0.0251) among case subjects, and ABCA1 (p =
0.0010) and DSCAML1 (p = 0.0084) among control subjects. Moreover, chi-square analysis
reveals significant differences in the genetic frequencies of LDLR (p = 0.0387) and APOA5
(p = 0.0353) polymorphisms respectively.
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Table 1. Comparison of the general characteristics of study participants.
Variables

Cases (n = 90)

Controls (n = 199)

P-value

Age (years)

40.9±10.8

39.2±2.0

0.0328

Female

73(81.1%)

157(78.9%)

Male

17(18.9%)

42(21.1%)

Gender b

Duration of treatment

0.7535

4.3±2.6

4.2±2.9

0.7796

420.7±28.9

410.6±21.2

0.0010

Systolic

112.5±13.8

114.8±17.6

0.2739

Diastolic

79.9±7.6

81.5±8.6

0.2309

Weight (kg)

76.9±13.8

76.6±14.5

0.8688

Height (m)

1.58±0.18

1.60±0.13

0.2861

Body mass index (BMI) (kg/m2)

33.8±2.4

31.5±1.1

<0.0001

Total Cholesterol

5.2±0.7

4.0±0.8

<0.0001

Triglycerides

1.4±0.7

1.4±0.6

0.9999

HDL-Cholesterol

0.7±0.3

1.2±0.5

<0.0001

CD4 counts
Blood pressure (mmHg)

Anthropometric indices

Lipid parameters (mmol/L)

LDL-Cholesterol

4.1±0.6

2.5±0.8

<0.0001

VLDL-Cholesterol

0.6±0.34

0.6±0.35

0.9999

Coronary Risk

10.5±0.3

6.2±4.8

<0.0001
0.4986

Dyslipidemic indices
High triglyceride b

8(8.9%)

26(13.1%)

High total cholesterol b

10(11.1%)

4(2.0%)

0.0184

Low HDL-Cholesterol b

90(100.0%)

107(53.8%)

<0.0001

High LDL-Cholesterol b

90(100.0%)

14(7.0%)

<0.0001

Cases: HIV seropositive with dyslipidemia, control: HIV seropositive without dyslipidemia
b

Fisher exact test, Dyslipidemia is defined as the presence of at least one NCEP-ATP III criteria reduced HDL (<1.03 mmol/L in males; <1.29 mmol/L in females),

raised TG �1.7 mmol/L, TC >6.2 mmol/L and LDL-C >3.37 mmol/L p<0.05 is considered statistically significant.
https://doi.org/10.1371/journal.pone.0227779.t001

Total Cholesterol (TC)
The case subjects who had the rare homozygous genotype for LDLR (p<0.0001), ABAC1
(p = 0.0287) DSCAML1 (p = 0.0003) and APOA5 (p = 0.0151) had a significantly higher level
of TC compared to the combined heterozygous and non-carriers’ genotypes [Table 3].

Triglycerides (TG)
Statistically significant differences were observed in TG levels for DSCAML1(p = 0.0006) and
LDLR (p = 0.0178) polymorphisms between homozygous rare genotype and heterozygous and
non-carriers’ genotypes among the case subjects. Similar patterns were observed for
DSCAML1 polymorphisms (p = 0.0133) among the control subjects [Table 3].

HDL Cholesterol (HDL-C)
There were significant differences in HDL-C levels with regards to APOA5 polymorphisms
(p = 0.0075) in case subjects. Thus, the combined heterozygous and non-carriers genotype had
high levels of HDL-C compared to the homozygous genotypes [Table 3].
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Table 2. Genotypic and allelic frequencies of polymorphisms of the Studied Population.
Polymorphisms

Cases
n (%)

LDLR (rs6511720) G>T

Controls

Allelic frequency

n (%)

T

G

T

0.81

0.19

0.89

0.11

G/G

61(67.8)

159(79.9)

G/T

24(26.7)

34(18.1)

T/T

5(5.5)
0.28184

ABCA1 (rs2066714) A>G

A

G

A

0.73

0.27

0.78

0.22

13(14.4)

18(9.1)

A/G

23(25.6)

53(26.6)

A/A

54(60.0)

0.3876

128(64.3)

HWE-P¥

0.0008

0.0010

C

T

C

T

0.8

0.2

0.81

0.19

C/C

60(66.7)

136(68.3)

C/T

24(26.7)

50(25.2)

T/T

6(6.6)

0.9585

13(6.5)

HWE-P¥

0.1138

APOA5 (rs662799) A>G

0.0387

0.1875

G

G/G

DSCAML1 (rs10892151) C>T

#P-value

4(2.0)

HWE-P¥

0.0084

A

G

A

G

0.76

0.24

0.84

0.16

A/A

56(62.2)

142(71.4)

A/G

25(27.8)

51(25.6)

G/G

9(10.0)

HWE-P¥

Allelic frequency

G

0.0353

6(3.0)
0.0251

0.1625

Cases: HIV seropositive with dyslipidemia, control: HIV seropositive without dyslipidemia, HWE-P: Hardy-Weinberg equation p-value
#

P-value represents chi-square test to compare genotype frequency between cases

¥

P-values for Chi-squared test for variant allelic frequency based on HWE; If p<0.05 means it not consistent with HWE

https://doi.org/10.1371/journal.pone.0227779.t002

LDL Cholesterol (LDL-C)
There were significant increased LDL-C levels in the rare-allelic subjects for LDLR (p<0.0001)
and DSCAML1 (p = 0.0078) polymorphisms compared to participants with heterozygous and
homogenous genotypes together among the case subjects [Table 3].
Individuals with G/G genotype for APOA5 (rs662799) polymorphisms were significantly
associated with an increased likelihood of developing dyslipidemia upon both univariate
[OR = 3.54, 95% CI(1.27–10.25; p = 0.0208)] and multivariate [OR = 2.38, 95% CI(1.06–6.54;
p = 0.0093)] logistic regression analyses holding other variables constant. A similar trend was
observed for rare homozygous genotype for LDLR polymorphisms; however, no statistically
significant association was noted [Table 4].
Table 5 shows the association between SNPs with lipid abnormalities after controlling for
age, gender, duration of treatment, CD4 counts and BMI respectively. Individuals with the
rare homozygous genotype of ABCA1 (G/G) [aOR = 10.7(1.3–88.7), p = 0.0280] and LDLR
(rs6511720) G>T [aOR = 61.2(7.6–493.4), p<0.0001) were more likely to have high levels of
TC levels. Moreover, subjects with T/T genotype of APOA5 (G/G) polymorphism were associated with increased levels of LDL-C [aOR = 2.2(1.4–6.0), p = 0.014].
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Table 3. Comparison of lipid parameters among study participants based on polymorphisms.
Variables
Polymorphisms

Cases

Controls

TC

TG

HDL-C

LDL-C

TC

TG

HDL-C

LDL-C

(mmol/L)

(mmol/L)

(mmol/L)

(mmol/L)

(mmol/L)

(mmol/L)

(mmol/L)

(mmol/L)

GG/GT

5.0±0.6

1.4±0.6

0.7±0.3

4.0±0.5

3.9±0.8

1.4±0.8

1.4±0.5

2.4±0.8

T/T

6.6±1.0

2.1±1.8

0.6±0.4

5.5±0.6

4.5±1.4

1.6±0.6

1.1±0.5

2.7±1.2

p-value

<0.0001

0.0178

0.895

<0.0001

0.1832

0.7018

0.2125

0.4866

AA/AG

5.1±0.7

1.3±0.7

0.6±0.3

4.1±0.1

3.8±0.9

1.4±0.9

1.2±0.6

2.4±0.8

G/G

5.5±0.8

1.8±0.7

0.8±0.4

4.4±0.6

4.2±1.1

1.4±0.06

1.1±0.4

2.7±0.9

p-value

0.0287

0.1148

0.2213

0.0968

0.247

0.8847

0.4001

0.3085

CC/CT

4.8±0.5

1.2±0.4

0.6±0.5

4.1±0.6

4.0±0.9

1.4±0.6

1.2±0.5

2.3±0.6

T/T

6.1±1.2

2.3±1.5

0.9±0.4

4.8±0.9

4.3±1.0

1.9±1.1

1.0±0.6

2.9±0.6

p-value

0.0003

0.0006

0.1036

0.0078

0.1946

0.0133

0.3933

0.0665

AA/AG

5.0±0.2

1.4±0.7

0.6±0.3

4.2±0.6

4.1±0.7

1.5±0.7

1.2±0.4

2.5±0.8

G/G

5.6±0.9

1.3±0.6

0.9±0.2

4.5±0.8

4.4±1.2

1.7±0.9

1.0±0.6

2.8±0.9

p-value

0.0151

0.7388

0.0075

0.1017

0.1563

0.3039

0.5685

0.2911

LDLR (rs6511720)
G>T

ABCA1 (rs2066714)
A>G

DSCAML1 (rs10892151)
C>T

APOA5 (rs662799)
A>G

TC: Total cholesterol, TG: Triglyceride, HDL-C: High density lipoprotein cholesterol, LDL-C: Low density lipoprotein cholesterol, Cases: HIV seropositive with
dyslipidemia, Control: HIV seropositive without dyslipidemia, Data is presented as mean±standard deviation, T-test was performed to obtained p-values, p<0.05
significant
https://doi.org/10.1371/journal.pone.0227779.t003

Table 4. Association between single nucleotide polymorphisms and the prevalence of dyslipidemia.
Variables

Dyslipidemia
Univariate logistic model

Polymorphisms

OR (95% CI)

Multivariate logistic model
P-value

aOR (95% CI)

0.1427

2.23(0.61–8.18)

0.2171

1.56(0.68–3.57)

0.8944

0.68(0.22–2.11)

0.0208

2.38((1.06–6.54

P-value

LDLR (rs6511720)
GG/GT
T/T

1
2.87(0.83–9.50)

1
0.2260

ABCA1 (rs2066714)
GG/AG
A/A

1
1.70(0.81 3.57)

1
0.2910

DSCAML1 (rs10892151)
CC/CT
T/T

1
1.02(0.38–2.63)

1
0.5090

APOA5 (rs662799)
AA/AG
G/G

1
3.54(1.27–10.25)

1
0.0093

Cases: HIV seropositive with dyslipidemia, Control: HIV seropositive without dyslipidemia, Odds ratio was calculated for each single nucleotide polymorphism using
rs6511720-GG, rs2066714-GG, rs10892151-CC, and rs662799-AA genotypes as a referent genotype OR = Odds ratio, CI = Confidence interval. A multivariate logistic
model was performed controlling for age, gender, duration of treatment, CD4 counts and BMI, p<0.05 considered statistically significant
https://doi.org/10.1371/journal.pone.0227779.t004
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Table 5. Association of SNPs with individual lipid abnormalities.
Variables
Polymorphisms

High TC
(mmol/L)

High TG
(mmol/L)

Low HDL-C
(mmol/L)

High-LDL-C
(mmol/L

aOR (95% CI)

aOR (95% CI)

aOR (95% CI)

aOR (95% CI)

61.2 (7.6–493.4)† ††

0.9 (0.1–1.0)

0.9 (0.2–3.9)

2.7 (0.7–10.6)

10.7 (1.3–88.7) †

1.8 (0.6–5.3)

1.3 (0.5–3.2)

1.7 (0.8–3.9)

DSCAML1 (rs10892151) T/T

2.3 (0.3–17.2)

1.7 (0.5–6.2)

0.8 (0.3–4.8)

0.9 (0.3–2.8)

APOA5 (rs662799) G/G

5.8 (0.8–44.9)

0.9 (0.2–4.6)

1.4 (0.4–4.8)

2.2 (1.4–6.0) †

LDLR (rs6511720) T/T
ABCA1 (rs2066714) G/G

TC = Total cholesterol, TG = Triglycerides, HDL-C = High Density Lipoprotein Cholesterol, LDL-C = Low Density Lipoprotein Cholesterol, Odds ratio was calculated
for the rare recessive polymorphism of rs6511720, rs2066714, rs10892151 and rs662799 genotypes using a combination of carriers and homozygotes as a referent
genotype, aOR = Adjusted odds ratio, CI = Confidence interval. A multivariate logistic model was performed controlling for age, gender, duration of treatment, CD4
counts and BMI
†

p<0.05

† ††

p<0.0001, p<0.05 = statistically significant

https://doi.org/10.1371/journal.pone.0227779.t005

S1 Table shows the demographic, clinical and metabolic characteristics of participants
stratified on the type of ART (NNRTI vs. PI). There were 3.5% (10/289) on PI-based treatment
whiles 279 (96.4%) were on NNRTI-based treatment. No statistically significant association
was observed between NNRTI AND PI- based treatment in relation to age (p = 0.2569), gender
(p = 0.6929), duration of treatment (p = 0.2092), systolic (p = 0.7638) and diastolic pressure
(p = 0.0865), weight (p = 0.2122), height (p = 0.7221) and BMI (0.6825) respectively. Seventyfive (15.6%) patients had hypertriglyceridemia, 24.9% had hypercholesterolemia and 71.9%
had low HDL-C in relation to metabolic parameters. PI-based subjects had significantly higher
levels of total cholesterol (6.09±0.56 vs. 4.34±0.96, p = 0.0001) and LDL cholesterol (4.60±0.55
vs. 2.95±1.16, p = 0.0001) and triglycerides (2.61±0.65 vs. 1.43±0.69, p = 0.0001) compared to
NNRTI-based subjects.

Discussion
Long term usage of ART has been implicated in several metabolic effects including dyslipidemia. However, this side effect varies among individuals on ART with comparable clinical and
demographic characteristics. As such, inherited predispositions and genetic factors have been
implicated in the cause of this metabolic alteration. The present study, therefore, assessed the
prevalence of SNPs and their associations with dyslipidemia in HIV patients on ART in
Ghana. Four candidate SNPs (rs2066714, rs6511720, rs662799, and rs10892151) reviewed
from PubMed were analyzed for associations with dyslipidemia among HIV-infected
individuals.
Several studies have shown the association between dyslipidemia and HIV patients on ART
[37, 38]. The prevalence rate of dyslipidemia among HIV patients on ART in this current
study was 31.1% with low HDL-C and high TC levels being the commonest lipid abnormalities. The observed prevalence of dyslipidemia is comparable to the range of reports from previous studies by Obirikorang et al.[9] and Ngala et al. [10] in Ghana and Kodogo et al. [10] in
Zimbabwe. However, it is lower compared to 78.9% prevalence rate reported by Limas et al.
[39] in a cross-sectional study among Brazilian HIV individuals on ART. Furthermore, our
observed results for low HDL-C, high TC and LDL-C levels among HIV patients on ART are
consistent with other studies [40, 41]. Results from the present study revealed that subjects
who received PI-based treatment had significantly increased levels of TC, LDL cholesterol and
triglycerides levels compared to the non-PI-based subjects. These findings are consistent with
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several case reports [42, 43] and cross-sectional studies [44, 45] which have reported that PI
exposures are associated with hypercholesterolemia and hypertriglyceridemia.
Our study demonstrated that the presence of the homozygous recessive/mutant genes for
LDLR, ABCA1, DSCAML1 and APOA5 genotypes among our study participants were very low
[Table 2]. Similar low frequencies in APOA5 and LDLR homozygotes mutant genes were
reported by Lazzaretti et al. [15] in a cross-sectional study among HIV-infected patients on
ART in the Brazilians population. Genome-wide associations studies have identified LDL-R
SNP rs6511720 (G>T), which is located in intron-1 of the gene, to be associated with lower
plasma levels of LDL-C and a lower risk of CHD [35]. Data from the GLGC consortium suggested that LDLR rs6511720 minor allele is prevalent in about 10% of the population and have
established that the allele is protective, being associated with lower levels of LDL-C [46].
Notwithstanding that, the frequency of recessive genes was low in this study population,
these findings are consistent with previous reports by Wang et al., [19] and Aragones et al. [24]
who did not find any significant differences in their studies with respect to prevalence of the
DSCAML1 and ABCA1 genotypes. Our findings demonstrated that the allelic frequencies for
ABCA1 and APOA5 polymorphisms were in not equilibrium with the Hardy-Weinberg equation among the case subjects as well as ABCA1 and DSCAML1 polymorphisms among the
control subjects. The low frequencies of the homozygotes of the rare alleles of these SNPS may
have contributed to the observed deviations.
A longitudinal study conducted by Rotgar et al. [47] validated the contribution of 42 SNPs
to dyslipidemia among the HIV-infected population treated with ART. The authors reported
that the degree of the contribution of SNPs and ART to dyslipidemia are similar and therefore
genetic information should be considered in addition to the dyslipidemic effect of ART agents
[47]. Results from the present study revealed that individuals with rs6511720 T/T genotype
recorded increased levels of TC, TG, and LDL-C compared to the combination of non-carriers
and heterozygous genotypes (GG/GT) [Table 3]. A further multivariate logistic model analysis
showed a strong association of LDLR polymorphisms with high levels of TC holding all other
confounding variables constants. A study by Lazzaretti et al. [15] reported that LDLR intron
19G>T (rs6511720) did not contribute to the plasma lipid levels in their dataset, and hence
may reflect a limited effect of this SNPs in HIV-infected patients. The inconsistency could be
due to different geographical settings and thereby calls for more research in these SNPs among
African descendants.
In this study, ABCA1 (rs2066714) G/G genotype was associated with an increased probability of having dyslipidemia. Furthermore, subjects with the homozygotes of the rare alleles of
ABCA1 have increased levels of TC compared to the common allelic (AA/AG) genotypes. As a
further matter, subjects carrying the minor allelic variant of ABCA1 were more likely to have
low levels of HDL cholesterol among the HIV population in the present study though no statistical significance was observed. These observations are congruent with previous reports demonstrated in literature that ABCA1 is associated with familial HDL deficiency. We should
mention here that low HDL-C was one of the commonest lipid abnormalities observed in this
study. Moreover, ABCA1 mediates the efflux of cellular cholesterol and phospholipids unto
ApoA-I and thereby plays a central role in regulating cellular cholesterol homeostasis, and
forming HDL[48, 49].
Individuals with T/T genotype for the DSCAML1 (rs10892151) polymorphisms among the
cases in this study had increased levels of TC, TG, and LDL-c compared with the other combined genotypes. Further analysis indicated that individuals with the homozygous minor
recessive gene (carriers) (T/T) were more likely to have increased levels of TC and LDL-C.
These observed findings are in parallel with previous reports by Aragones et al. [24] who
reported a strong association between the expression of the rs10892151 T allelic variant and
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dyslipidemia, mostly hypertriglyceridemia and decreased HDL-cholesterol levels. In contrast,
Pollin et al., [23] observed that rs10892151 T carriers had lower fasting and postprandial
serum triglycerides values than non-carriers, and they found a linkage disequilibrium with an
APOC3 null mutation, which was likely the result of a founder effect in their high-fat feeding
intervention study. Evidence provided in the literature shows that carriers of this null mutation
have low circulating apolipoprotein (Apo) C-III levels and reduced fasting and post-prandial
triglyceride concentrations [23], which is likely due to the well-established function of Apo
C-III as an inhibitor of lipoprotein lipase[50].
This current study showed that carriers of the minor allelic variant of the APOA5
(rs662799) A>G SNP gene, were 2 times more likely to developed dyslipidemia. Moreover,
individuals with homozygotes (G/G) have significantly increased levels of TC and LDL cholesterol compared to wild type and heterozygote combined (AA/AG). Previous studies have
found rs662799 to be associated with elevated plasma triglyceride levels as well as HDL-C and
total cholesterol [21]. Two polymorphisms in the APOA5 gene, −1131T>C and S19W
(56C>G), have already been shown to be associated with elevated triglyceride levels in different populations[51, 52]. This study, however, considered the APOA5 (rs662799) A>G variant
and found that HIV individuals with at least one G allele had higher TC and LDL cholesterol
levels.
Lazzaretti et al. [15] reported that APOA5 −1131T>C (rs662799) was associated with
plasma triglycerides (TG) and low-density lipoprotein cholesterol levels (LDL-C) as well as
high-density-lipoprotein cholesterol levels. To the best of our knowledge, this study is the first
to investigate the APOA5 (rs662799) A>G variant in HIV patients in a Ghanaian population.
Another study by Echeverria et al. [53] reported that polymorphisms in genes associated with
the development of atherogenic dyslipidemia, especially variants in the APOA5 gene, can influence the circulating CD4 T-cell levels in chronically HIV-infected patients. Although a previous study has reported the effect of APOA5 on CD4 levels, individuals with the minor allelic
variant of APOA5 (rs662799) A>G have a significant likelihood of developing dyslipidemia in
HIV subjects on ART after controlling for CD4 counts as well as age, gender, duration of treatment and BMI.
This study has strength in it possibly being the first study to assess the prevalence of SNPs
and their associations with dyslipidemia in the Ghanaian population as a proof of concept.
Although previous reports have shown an uneven continuous rate of the incidence of HIV in
the Ghanaian population with more than 60% of people living with HIV are females [54], the
proportion of HIV- infected females in this study population was much higher than males
which could affect the generalizations of our findings to the HIV population in Ghana. In
addition, our study is limit by the fact that the number of investigated polymorphisms is not
comprehensive, notwithstanding, this is a baseline study for future exploratory analysis of
SNPs and their associations with dyslipidemia among HIV patients on ART in Ghana.

Conclusion
This study has highlighted the evidence that SNPs in four candidate genes are present in HIV
patients exposed to ART in the Ghanaian population. Dyslipidemia remains prevalent among
HIV patients. SNPs were found to associate with dyslipidemia especially variants in
APOA5-rs662799 and LDLR-rs651172 respectively. This finding provides baseline information that necessitates a pre-symptomatic strategy for monitoring dyslipidemia in ART-treated
HIV patients Findings from this study should be validated in a longitudinal case-control study
considering the disease and its therapeutic implications. These candidate SNPs if validated
would help in serving as potential biomarkers to detect individuals at risk for dyslipidemia.
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